Patent
   RE32011
Priority
Dec 21 1983
Filed
Dec 21 1983
Issued
Oct 22 1985
Expiry
Dec 21 2003
Assg.orig
Entity
Large
94
28
all paid
8. An improved immunoadsorbent for isolation and purification of viii:C from viii:C/viii:RP comprising a monoclonal antibody specific to viii:RP bound to solid particles.
15. In a method for purifying factor viii procoagulant activity protein from plasma or concentrate, the improvement comprising the step of passing said plasma or concentrate through a chromatographic type column having adsorbent to which is bound monoclonal antibodies which is specific to viii:RP and eluting the viii-C therefrom.
1. An improved method of preparing factor viii procoagulant activity protein comprising the steps of
(a) adsorbing a viii:C/viii:RP complex from a plasma or commercial concentrate source onto particles bound to a monoclonal antibody specific to viii:RP,
(b) eluting the viii:C,
(c) adsorbing the viii:C obtained in step (b) in another adsorption to concentrate and further purify same,
(d) eluting the adsorbed viii:C, and
(e) recovering highly purified and concentrated viii:C.
2. A method according to claim 1, wherein the elutant used in each of steps (b) and (d) is a saline solution.
3. The method according to claim 2, wherein the saline solution is calcium chloride.
4. The method according to claim 3, wherein the concentration of said calcium chloride solution used in steps (b) and (d) ranges from about 0.25 M to about 0.5 M.
5. The method according to claim 1, wherein said adsorbent particles in step (a) are agarose.
6. The method according to claim 1, wherein aminohexyl agarose is employed in step (c) as the adsorbent.
7. The method according to claim 6, wherein calcium chloride solution is employed as the elutant in steps (b) and (d), concentration of said calcium chloride solution ranging from about 0.25 M to about 0.5 M in step (b) and from about 0.25 M to about 0.5 M in step (d).
9. The improved immunoadsorbent of claim 8, wherein said solid particles comprise a resin.
10. The improved immunoadsorbent of claim 9, wherein said resin comprises agarose.
11. The improved immunoadsorbent of claim 10, wherein said agarose is cross-linked agarose.
12. The improved immunoadsorbent of claim 11, wherein said immunoadsorbent has a coupling density of 3 to 4 g of monoclonal antibody per liter of agarose.
13. Highly purified and concentrated human or porcine viii:C prepared in accordance with the method of claim 1.
14. Highly purified and concentrated human or porcine viii:C prepared in accordance with the method of claim 6.
16. The method according to claim 15, wherein said adsorbent is agarose and said elutant is a saline solution.
17. A viii:C of claim 13, wherein said viii:C is human viii:C. 18. A viii:C of claim 14, wherein said viii:C is human viii:C. 19. An improved immunoadsorbent of claim 8 wherein said monoclonal antibody remains bound to viii:RP during elution of viii:C. 20. An improved immunoadsorbent of claim 19, wherein said elution is carried out with a saline solution. 21. An improved immunoadsorbent of claim 20 wherein said solution contains calcium ions. 22. An improved immunoadsorbent of claim 21, wherein said solution is calcium chloride. 23. An improved immunoadsorbent of claim 22, wherein the concentration of said calcium chloride is from 0.25 M to about 0.5 M. 24. A human viii:C preparation having a potency in the range of 134 to 1172 units per ml, and
being substantially free of viii:RP. 25. A human viii:C preparation of claim 24, wherein the viii:C concentration is at least 160,000 fold purified relative to viii:C in plasma. 26. A human viii:C preparation of claim 24, wherein the ratio of viii:C to viii:RP is greater than 100,000 times the ratio in plasma. 27. A human viii:C preparation of claim 24, wherein said viii:C is isolated from viii:C/viii:RP and 90-100 percent of the viii:RP has been
removed. 28. A human viii:C preparation having a specific activity greater than 2240 units/mg. 29. A human viii:C preparation of claim 28 wherein the potency is in the range of 134 to 1172 units/ml. 30. An improved method of preparing factor viii procoagulant activity protein comprising the steps of
(a) adsorbing a viii:C/viii:RP complex from a plasma or commercial concentrate source onto a substrate to which is bound a monoclonal antibody specific to viii:RP,
(b) eluting the viii:C,
(c) adsorbing the viii:C obtained in step (b) in another adsorption to concentrate and further purify same,
(d) eluting the adsorbed viii:C, and
(e) recovering highly purified and concentrated viii:C.
A method according to claim 30, wherein said substrate is a resin. 32. A method according to claim 30, wherein said substrate is comprised of particles. 33. An improved immunoadsorbent for isolation and purification of viii:C from viii:C/viii:RP comprising a monoclonal antibody specific to viii:RP bound to a substrate. 34. Highly purified and concentrated human or porcine viii:C prepared in accordance with the method of claim 30. 35. In a method for purifying factor viii procoagulant activity protein from plasma or concentrate, the improvement comprising the step of passing said plasma or concentrate over a substrate to which is bound monoclonal antibodies which are specific to viii:RP and eluting the viii:C therefrom. 36. The method according to claim 35, wherein said substrate is agarose and said elutant is a saline solution.

Zimmerman, Theodore S., Fulcher, Carol A.

Patent Priority Assignee Title
10064946, May 14 2010 Amgen Inc. High concentration antibody formulations
10233237, Nov 21 2012 Amgen Inc Heterodimeric immunoglobulins
10273293, Sep 17 2007 Amgen Inc. Method for inhibiting bone resorption
10308704, Nov 26 2008 Amgen Inc. Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof
10407487, Mar 06 2007 Amgen Inc. Variant activin receptor
10538584, Aug 04 2011 Amgen Inc Methods for treating bone gap defects
10562964, May 03 2005 Amgen Inc. Methods for isolating antibodies that bind sclerostin
10799583, Jul 05 2012 UCB Pharma, S.A. Treatment for bone diseases
11040102, May 14 2010 Amgen Inc. High concentration antibody formulations
11091537, Sep 17 2007 Amgen Inc. Method for inhibiting bone resorption
11414482, Nov 08 2016 University of Miami Anti-secretogranin III (SCG3) antibodies and uses thereof
11466078, Nov 21 2012 Amgen Inc. Heterodimeric immunoglobulins
11466079, Mar 30 2018 Amgen Inc. C-terminal antibody variants
11541070, Feb 01 2013 Atara Biotherapeutics, Inc. Administration of an anti-activin-A compound to a subject
11576970, Mar 10 2016 UCB BIOPHARMA SRL Pharmaceutical formulations
11685770, Nov 26 2008 Amgen Inc. Stabilized receptor polypeptides and uses thereof
11702468, Jun 16 2003 UCB Pharma, S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
11851483, Dec 12 2014 UCB PHARMA, S A Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen
11858983, Mar 30 2018 Amgen Inc. C-terminal anti-sclerostin antibody variants
11896667, Jul 05 2012 UCB Pharma S.A. Treatment for bone diseases
4831118, Aug 07 1987 FLEET CAPITAL CORPORATION, AS AGENT Flouroplastic immunoaffinity columns for purification of blood proteins
4877608, Nov 09 1987 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
4925574, Jun 26 1985 HER MAJESTY THE QUEEN AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE OF HER MAJESTY S CANADIAN GOVERNMENT Purification of hemoglobin and modified hemoglobin by affinity chromatography
5006642, Jun 29 1987 ARMOUR PHARMACEUTICAL PRODUCTS INC Purification of von Willebrand Factor by affinity chromatography
5043428, Aug 31 1984 CSL Behring GmbH Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
5198349, Jan 03 1986 Genetics Institute, LLC Method for producing factor VIII:C and analogs
5200510, Jun 16 1987 ZymoGenetics, Inc. Method for purifying factor VIII:C, von Willebrand factor and complexes thereof
5288853, Apr 30 1992 GRIFOLS INC Factor viii purification process
5362854, Mar 31 1983 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
5364771, Apr 07 1992 Emory University Hybrid human/porcine factor VIII
5470954, Mar 31 1987 Baxter International Inc. Ultrapurification process for factor VIII
5605884, Oct 29 1987 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
5618788, Apr 20 1984 Genentech, Inc. Preparation of functional human factor VIII and pharmaceutical treatment therewith
5618789, Apr 20 1984 Genentech, Inc. Functional human factor VIII
5633150, Apr 20 1984 Genentech, Inc Preparation of functional human factor VIII
5654147, Apr 20 1984 Genentech, Inc Method of hybridization using oligonucleotide probes
5659017, Nov 07 1995 GRIFOLS INC Anion exchange process for the purification of Factor VIII
5663060, Apr 07 1992 Emory University Hybrid human/animal factor VIII
5668108, Apr 20 1984 Genentech, Inc. Preparation of functional human factor VIII and pharmaceutical treatment therewith
5683905, Apr 20 1984 Genentech, Inc. Vectors and cell lines capable of correctly splicing exon regions
5744446, Apr 07 1992 Emory University Hybrid human/animal factor VIII
5747337, Mar 31 1983 The Scripps Research Institute Factor VIII coagulant polypeptides and monoclonal antibodies to them
5783671, Jan 12 1984 Chiron Corporation; Novo Nordisk A/S Method and composition for preparation of factor VIIIC
5888974, Apr 07 1992 Emory University Hybrid human/animal factor VIII
5994310, Sep 03 1998 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
6248555, Aug 31 1995 General Hospital Corporation, The Genetic alterations related to familial alzheimer's disease
6864235, Apr 01 1999 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
6911429, Apr 01 1999 TRANSITION THERAPEUTICS INC Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
7063850, Dec 22 1998 University of Tennessee Research Foundation Protective antigen of group A Streptococci
7087420, Jul 11 1997 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
7141719, Sep 09 1997 Cambia Microbial β-Glucuronidase genes, gene production and uses thereof
7270827, Oct 26 2001 University of Tennessee Research Foundation Multivalent streptococcal vaccine compositions and methods for use
7572899, Nov 27 1998 UCB S A ; UCB PHARMA S A Compositions and methods for increasing bone mineralization
7592429, May 03 2005 Amgen Inc Sclerostin-binding antibody
7659375, Aug 21 1998 Immunex Corporation Human IL-1 epsilon DNA and polypeptides
7700277, Jul 26 2003 AstraZeneca AB Use of polymorphisms in human OATP-C associated with an effect on statin pharmacokinetics in humans in statin therapy
7758858, Nov 27 1998 UCB S A ; UCB PHARMA S A Antibodies associated with alterations in bone density
7799523, Apr 03 2002 Erasmus University Rotterdam Association of polymorphisms in the SOST gene region with bone mineral density
7868134, Jun 16 2003 UCB PHARMA S A Immunogenic peptides derived from sclerostin
7872106, May 03 2005 UCB PHARMA S A Sclerostin-binding antibodies
7977312, Nov 27 1998 UCB S A ; UCB PHARMA S A Compositions and methods for increasing bone mineralization
7985834, Jun 16 2003 UCB PHARMA S A Compositions and methods for increasing bone mineralization
7994299, Nov 27 1998 UCB S A ; UCB PHARMA S A Compositions and methods for increasing bone mineralization
8003108, May 03 2005 UCB SA Sclerostin epitopes
8017120, Sep 17 2007 Amgen Inc Method for inhibiting bone resorption
8329176, Sep 17 2007 Amgen Inc. Method for inhibiting bone resorption
8383801, May 03 2005 Amgen Inc. Polynucleotide encoding a sclerostin-binding antibody
8410043, Nov 26 2008 Amgen Inc Stabilized activin IIB receptor polypeptides and uses thereof
8440193, Sep 17 2007 Amgen Inc. Method for inhibiting bone resorption
8563271, Jun 16 2003 UCB PHARMA S A Antibodies specific for sclerostin and methods for increasing bone mineralization
8637643, May 03 2005 UCB PHARMA S A Sclerostin binding antibody
8715663, May 03 2005 Amgen Inc. Epitopes
8986685, Nov 27 1998 UCB S A ; UCB PHARMA S A Compositions and methods for increasing bone mineralization
8992911, Jun 16 2003 UCB PHARMA S A Antibodies specific for sclerostin and methods for increasing bone mineralization
8999917, Mar 06 2007 Amgen Inc. Variant activin receptor polypeptides and uses thereof
9011856, Jun 16 2003 UCB PHARMA S A Antibodies specific for sclerostin and methods for increasing bone mineralization
9089553, Sep 17 2007 Amgen Inc. Method for inhibiting bone resorption
9133272, Mar 01 2011 Amgen Inc Bispecific binding agents
9145457, Mar 25 2011 Amgen Inc Sclerostin antibody crystals and formulations thereof
9296812, May 03 2005 Amgen Inc. Sclerostin binding antibodies
9352043, May 14 2010 Amgen Inc High concentration antibody formulations
9353174, May 03 2005 Amgen Inc. Epitopes
9382309, Mar 06 2007 Amgen Inc. Variant activin IIB receptor
9447165, Mar 06 2007 Amgen Inc Variant activin IIB receptor
9610327, Dec 19 2011 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
9617333, Mar 25 2011 Amgen Inc. Sclerostin antibody crystals and formulations thereof
9657090, Dec 28 2011 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
9657095, Jun 16 2003 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
9791462, Nov 27 1998 UCB Pharma, S.A. Compositions and methods for increasing bone mineralization
9809638, Mar 06 2007 Amgen Inc. Variant activin receptor
9822173, Nov 21 2012 Amgen Inc Heterodimeric immunoglobulins
9913900, Dec 28 2011 Amgen Inc.; The Regents of the University of Michigan Method of treating alvelor bone loss through the use of anti-sclerostin antibodies
9920114, Mar 25 2011 Amgen Inc. Antibody formulations
9925260, Jul 05 2012 UCB PHARMA S A Treatment for bone diseases
Patent Priority Assignee Title
3631018,
3652530,
3682881,
3973002, Apr 12 1974 E. R. Squibb & Sons, Inc. Antihemophilic factor
4069216, Jun 16 1975 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
4137223, Apr 11 1975 Edward Shanbrom, Inc. Method of preserving blood plasma II
4188318, Jun 16 1975 INSTITUT MERIEUX, A CORP OF FRANCE Simplified method for preparation of high yield, high purity Factor VIII concentrate
4203891, Dec 19 1977 CANADIAN RED CROSS SOCIETY, THE Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin
4272521, Jul 16 1979 Cutter Laboratories, Inc. Purified immune serum globulin
4296027, Aug 31 1977 The Regents of the University of Minnesota Pure intravenous human and animal gamma globulins
4302445, Jan 18 1980 MERIEUX S A Method for concentrating and purifying antihemophilic factor or factor VIII
4348315, Dec 20 1979 Process in purification and concentration of the factor VIII-complex
4361510, May 27 1980 Cutter Laboratories, Inc. Blood coagulation promoting product
4361550, Dec 04 1979 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
4361647, May 22 1980 Palo Alto Medical Research Foundation Sandwich immunoassay and compositions for use therein
4362867, Dec 10 1980 RESEARCH CORPORATION TECHNOLOGIES, INC , A NONPROFIT CORP OF DE; Medical University of South Carolina Recombinant cDNA construction method and hybrid nucleotides useful in cloning
4364861, May 27 1980 IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCHE PRODUKTE IMMUNO , A CORP OF AUSTRIA Blood-coagulation-promoting products and methods of preparing them
4364932, Sep 18 1979 Ortho Pharmaceutical Corporation Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same
4364933, Dec 04 1979 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
4364934, Dec 04 1979 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
4364935, Dec 04 1979 Ortho Pharmaceutical Corporation Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
4364936, Jan 08 1980 Ortho Pharmaceutical Corporation Monoclonal antibody to a human monocyte antigen and methods of preparing same
4364937, Jan 08 1980 Ortho Pharmaceutical Corporation Monoclonal antibody to a human T cell antigen and methods of preparing same
4373932, Jan 11 1980 Akzona Incorporated Application of water-dispersible hydrophobic dyes or pigments as labels in immunoassays
4376110, Aug 04 1980 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
4381292, Nov 14 1980 BOARD OF TRUSTEES OF LELAND STANFORD JR UNIVERSITY, STANFORD UNIVERISTY, A CORP OF CA Anti-human T-lymphocyte monoclonal antibody
4381295, Apr 26 1979 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
EP38642,
//
Executed onAssignorAssigneeConveyanceFrameReelDoc
Dec 21 1983Scripps Clinic and Research Foundation(assignment on the face of the patent)
Oct 30 1991Scripps Clinic and Research FoundationSCRIPPS RESEARCH INSTITUTE, THE, A CORP OF CAASSIGNMENT OF ASSIGNORS INTEREST 0061670046 pdf
Date Maintenance Fee Events
Apr 21 1986M170: Payment of Maintenance Fee, 4th Year, PL 96-517.
May 01 1990M171: Payment of Maintenance Fee, 8th Year, PL 96-517.
May 11 1990ASPN: Payor Number Assigned.
May 02 1994M185: Payment of Maintenance Fee, 12th Year, Large Entity.
May 16 1994ASPN: Payor Number Assigned.
May 16 1994RMPN: Payer Number De-assigned.


Date Maintenance Schedule
Oct 22 19884 years fee payment window open
Apr 22 19896 months grace period start (w surcharge)
Oct 22 1989patent expiry (for year 4)
Oct 22 19912 years to revive unintentionally abandoned end. (for year 4)
Oct 22 19928 years fee payment window open
Apr 22 19936 months grace period start (w surcharge)
Oct 22 1993patent expiry (for year 8)
Oct 22 19952 years to revive unintentionally abandoned end. (for year 8)
Oct 22 199612 years fee payment window open
Apr 22 19976 months grace period start (w surcharge)
Oct 22 1997patent expiry (for year 12)
Oct 22 19992 years to revive unintentionally abandoned end. (for year 12)